THE PRECISION APPROACH:
TARGET EGFR
2004
2008
TIME LINE
EPIC
: phase III trial of
CETUXIMAB plus
irinotecan
after...oxaliplatin failure
Sobrero AF. J Clin Oncol 2008
BOND
:
CETUXIMAB plus irinotecan
in
irinotecan-refractory
Cunningham D. N Engl J Med. 2004
Rash is predictive!!!
but not
EGFR
17
